SPRB
Spruce Biosciences, Inc. NASDAQ Listed Oct 9, 2020$56.57
Mkt Cap $77.6M
52w Low $7.00
6.0% of range
52w High $838.12
50d MA $60.97
200d MA $97.37
P/E (TTM)
-1.1x
EV/EBITDA
-0.5x
P/B
1.0x
Debt/Equity
0.0x
ROE
-91.6%
P/FCF
-2.0x
RSI (14)
—
ATR (14)
—
Beta
3.68
50d MA
$60.97
200d MA
$97.37
Avg Volume
63.8K
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
2001 Junipero Serra Boulevard · Daly City, CA 94014 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -12.87 | -9.58 | +25.6% | 62.11 | +0.6% | +1.1% | +2.2% | -6.7% | +0.3% | +1.5% | — |
| Nov 10, 2025 | AMC | -15.56 | -14.58 | +6.3% | 115.61 | +2.8% | -2.6% | -9.3% | +10.1% | -5.5% | +2.3% | — |
| Aug 14, 2025 | AMC | -18.05 | -3.50 | +80.6% | 8.75 | +9.7% | +3.0% | -0.7% | -0.4% | -6.1% | +1.6% | — |
| May 6, 2025 | AMC | -18.80 | -24.06 | -28.0% | 5.33 | -5.6% | +2.8% | -1.5% | +4.3% | -4.1% | -8.3% | — |
| Apr 2, 2025 | AMC | -0.24 | -0.23 | +4.2% | 21.98 | -2.7% | +0.0% | -4.1% | -2.5% | +1.8% | +5.7% | — |
| Nov 11, 2024 | AMC | -20.30 | -15.79 | +22.2% | 39.98 | -2.5% | -1.3% | -2.8% | +2.0% | -5.8% | -3.7% | — |
| Aug 12, 2024 | AMC | -24.81 | -16.54 | +33.3% | 31.35 | +0.5% | +3.8% | -0.5% | +1.9% | +2.7% | +4.0% | — |
| May 13, 2024 | AMC | -24.06 | -21.05 | +12.5% | 60.38 | +0.6% | +2.5% | -3.0% | -3.8% | -2.6% | +0.4% | — |
| Mar 13, 2024 | AMC | -30.83 | -17.29 | +43.9% | 389.25 | -77.3% | -84.4% | -0.4% | -6.1% | -1.3% | -0.5% | — |
| Nov 13, 2023 | AMC | -25.56 | -22.56 | +11.7% | 81.00 | +3.7% | -3.7% | +10.6% | +16.5% | +0.7% | +0.7% | — |
| Aug 14, 2023 | AMC | -27.82 | -24.06 | +13.5% | 164.25 | -5.0% | -1.4% | +2.8% | +5.0% | +0.9% | -6.4% | — |
| May 15, 2023 | AMC | -31.58 | -30.08 | +4.7% | 163.50 | +0.0% | +0.9% | +4.5% | -1.7% | +3.1% | +5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Craig Hallum | Initiates | Buy | $140 | $54.37 | $56.09 | +3.2% | +5.2% | -4.2% | +1.4% | +3.2% | -0.1% |
| Mar 10 | Citizens | Maintains | Market Outperform → Market Outperform | — | $62.11 | $62.48 | +0.6% | +1.1% | +2.2% | -6.7% | +0.3% | +1.5% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.11 | $62.48 | +0.6% | +1.1% | +2.2% | -6.7% | +0.3% | +1.5% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.48 | $53.01 | -0.9% | -1.6% | -5.5% | +7.8% | +8.7% | +0.9% |
| Dec 3 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $89.20 | $88.26 | -1.1% | +1.1% | +0.3% | -11.6% | +2.1% | +16.5% |
| Nov 11 | Citizens | Maintains | Market Outperform → Market Outperform | — | $115.61 | $118.81 | +2.8% | -2.6% | -9.3% | +10.1% | -5.5% | +2.3% |
| Oct 28 | JMP Securities | Upgrade | Market Perform → Market Outperform | — | $123.02 | $131.54 | +6.9% | +1.2% | -5.2% | -9.1% | +2.7% | -4.9% |
| Oct 21 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $148.16 | $148.00 | -0.1% | -12.6% | +8.5% | -7.5% | +2.6% | -7.7% |
| Apr 16 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $9.90 | $9.75 | -1.5% | -6.8% | -3.3% | +1.7% | +7.4% | +2.4% |
| Dec 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $28.73 | $28.88 | +0.5% | +1.6% | +3.8% | -5.4% | +0.0% | +4.7% |
| Dec 12 | Guggenheim | Maintains | Neutral → Neutral | — | $32.25 | $30.75 | -4.7% | -10.0% | -1.0% | +1.6% | +3.8% | -5.4% |
| Dec 11 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $40.28 | $31.58 | -21.6% | -19.9% | -10.0% | -1.0% | +1.6% | +3.8% |
| Dec 11 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $40.28 | $31.58 | -21.6% | -19.9% | -10.0% | -1.0% | +1.6% | +3.8% |
| Dec 11 | Oppenheimer | Downgrade | Outperform → Perform | — | $40.28 | $31.58 | -21.6% | -19.9% | -10.0% | -1.0% | +1.6% | +3.8% |
| Nov 12 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $39.98 | $39.00 | -2.5% | -1.3% | -2.8% | +2.0% | -5.8% | -3.7% |
| Aug 13 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $31.35 | $31.50 | +0.5% | +3.8% | -0.5% | +1.9% | +2.7% | +4.0% |
| Jun 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $49.88 | $50.48 | +1.2% | +1.0% | -3.3% | +0.5% | -3.5% | -15.9% |
| Mar 14 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $389.25 | $88.50 | -77.3% | -84.4% | -0.4% | -6.1% | -1.3% | -0.5% |
| Mar 14 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $389.25 | $88.50 | -77.3% | -84.4% | -0.4% | -6.1% | -1.3% | -0.5% |
| Mar 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $389.25 | $88.50 | -77.3% | -84.4% | -0.4% | -6.1% | -1.3% | -0.5% |
| Mar 14 | Guggenheim | Downgrade | Buy → Neutral | — | $389.25 | $88.50 | -77.3% | -84.4% | -0.4% | -6.1% | -1.3% | -0.5% |
| Mar 14 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $389.25 | $88.50 | -77.3% | -84.4% | -0.4% | -6.1% | -1.3% | -0.5% |
| Mar 14 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $389.25 | $88.50 | -77.3% | -84.4% | -0.4% | -6.1% | -1.3% | -0.5% |
| Mar 5 | RBC Capital | Maintains | Outperform → Outperform | — | $402.75 | $399.00 | -0.9% | -9.1% | +6.4% | +3.9% | -5.2% | +0.2% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $411.75 | $420.75 | +2.2% | -1.8% | -4.5% | +4.3% | -6.9% | +5.4% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $101.25 | $104.25 | +3.0% | +0.7% | +0.7% | -0.7% | +4.4% | -1.4% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $190.50 | $193.50 | +1.6% | -2.0% | -1.6% | +0.4% | -1.6% | +0.4% |
| Sep 13 | RBC Capital | Maintains | Outperform → Outperform | — | $190.50 | $193.50 | +1.6% | -2.0% | -1.6% | +0.4% | -1.6% | +0.4% |
| Sep 8 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $167.25 | $180.00 | +7.6% | +0.0% | +2.2% | +11.4% | -2.0% | -1.6% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $174.75 | $174.00 | -0.4% | +0.9% | -6.4% | -0.5% | +0.0% | +0.5% |
| Aug 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $174.75 | $174.00 | -0.4% | +0.9% | -6.4% | -0.5% | +0.0% | +0.5% |
| Aug 16 | JMP Securities | Maintains | Outperform → Outperform | — | $162.00 | $162.00 | +0.0% | +2.8% | +5.0% | +0.9% | -6.4% | -0.5% |
| Aug 15 | RBC Capital | Maintains | Outperform → Outperform | — | $164.25 | $156.00 | -5.0% | -1.4% | +2.8% | +5.0% | +0.9% | -6.4% |
| Jun 20 | JMP Securities | Maintains | Market Outperform → Outperform | — | $178.50 | $172.50 | -3.4% | -3.8% | -0.9% | -3.1% | +5.5% | -4.3% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $172.50 | $169.50 | -1.7% | +4.3% | -1.2% | -0.4% | +0.8% | -3.8% |
| May 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $184.50 | $189.00 | +2.4% | -0.4% | +6.1% | -13.1% | +7.5% | -1.2% |
| May 16 | Credit Suisse | Maintains | Outperform → Outperform | — | $163.50 | $163.50 | +0.0% | +0.9% | +4.5% | -1.7% | +3.1% | +5.6% |
| May 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $163.50 | $163.50 | +0.0% | +0.9% | +4.5% | -1.7% | +3.1% | +5.6% |
| May 16 | RBC Capital | Maintains | Outperform → Outperform | — | $163.50 | $163.50 | +0.0% | +0.9% | +4.5% | -1.7% | +3.1% | +5.6% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $169.50 | $176.25 | +4.0% | +1.3% | -1.7% | +2.7% | -2.4% | -5.1% |
| Mar 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $171.75 | $171.00 | -0.4% | +1.3% | -0.9% | +0.4% | -2.2% | +1.3% |
| Feb 13 | RBC Capital | Maintains | Outperform → Outperform | — | $208.50 | $216.00 | +3.6% | -5.0% | +2.3% | +1.1% | -8.1% | +2.4% |
| Jan 8 | JMP Securities | Maintains | Market Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Nov 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $89.25 | $87.00 | -2.5% | -3.4% | -5.2% | +2.8% | -9.8% | +8.9% |
| Mar 16 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $138.75 | $141.75 | +2.2% | +4.9% | +5.2% | -2.0% | +4.0% | +4.3% |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | $141.00 | $142.50 | +1.1% | -1.6% | +4.9% | +5.2% | -2.0% | +4.0% |
| Nov 23 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $202.50 | $204.00 | +0.7% | -1.9% | +5.7% | -1.8% | -6.2% | +0.0% |
| Nov 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $328.87 | $322.50 | -1.9% | -29.8% | +1.0% | -5.5% | -0.3% | -7.8% |
| Nov 16 | Credit Suisse | Maintains | Outperform → Outperform | — | $328.87 | $322.50 | -1.9% | -29.8% | +1.0% | -5.5% | -0.3% | -7.8% |
| Nov 16 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $328.87 | $322.50 | -1.9% | -29.8% | +1.0% | -5.5% | -0.3% | -7.8% |
No insider trades available.
8-K · 1.01
! Medium
Spruce Biosciences, Inc. -- 8-K 1.01: Underwriting / Securities
Spruce Biosciences engaged Leerink Partners as underwriter, likely preparing for a securities offering to raise capital for clinical development and operations.
Apr 22
8-K · 1.02
!! High
Unknown — 8-K 1.02: Material Agreement Terminated
Kaken's termination of this supply and royalty agreement eliminates a revenue stream for the company, likely pressuring earnings and cash flow, which investors should monitor for potential stock weakness.
Mar 20
8-K · 5.02
!!! Very High
Spruce Biosciences, Inc. -- 8-K 5.02: Executive Change
Spruce Biosciences appointed experienced pharma executive Corwin Dale Hooks as Chief Commercial Officer, bringing leadership from Applied Therapeutics to strengthen commercial operations.
Mar 9
8-K · 8.01
!! High
Spruce Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Spruce Biosciences presented new analyses showing its TA-ERT treatment stabilized communication and motor skills in MPS IIIB patients, potentially strengthening clinical evidence for the rare disease therapy.
Feb 5
Data updated apr 27, 2026 2:38am
· Source: massive.com